ADGM · Adagio Medical Holdings, Inc.
$0.56
-0.02 (-3.28%)
At close · Sep 11
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As of the report date, we do not believe our existing cash and cash equivalents are sufficient to fund our operating and capital expenditure requirements for at least 12 months from the date of issuance of the audited consolidated financial statements included in this Report. Based on our current research and development plans, we expect to have sufficient resources to fund our planned operations into the fourth quarter of 2026. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our capital resources sooner than expected. No assurance can be given as to whether additional needed financing will be available on terms acceptable to us, if at all. If sufficient funds on acceptable terms are not available when needed, we may be required to suspend or forego certain planned activities. Failure to manage discretionary spending or raise additional financing, as needed, could adversely impact our ability to achieve our intended business objectives and may have an adverse effect on our results of operations and future prospects. These factors raise substantial doubt about our ability to continue as a going concern for the twelve-month period from the date of this filing with the SEC.”View the 10-Q filed Aug 11, 2026
Market Cap
$12.46M
Shares
22.21M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.56
Open$0.56
Day$0.56–0.61
52W close$0.38–2.36
Avg vol 30d17.1M
Short int259K · 1.2% float · 1.0d
Short vol17%
Last earningsMar 27, 2026
DataAug 2024–Sep 2026
Filing10-Q · Aug 11
Up next
filed Aug 11, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$27.14M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$17.10M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+44.4%
Year over year · more shares
Price change (1Y)
-66.2%
Trailing year
Short interest
1.2%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.8 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−37%
below
Price vs 50-day avg
−2%
below
RSI (14)
47
neutral
MACD trend
Positive
52-week position
9%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−19%
trailing
6-month return
−50%
trailing
YTD return
−46%
this year
Relative strength
−68%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+4% holders QoQ · +4 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.17% of float · ▼ -20.4% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
24 holders — near 2-yr high, broad support
Squeeze score
28
low risk · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
+97%
Y/Y
Free cash flow
$-19.4M
Balance sheet
$3.9M
net debt
Quant / Vol
risk profile
Volatility
130%
annualized · 1-yr
Max drawdown
−84%
past year
ATR
11.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−37%
Bearish
Price vs 50-day avg
−2%
Neutral
RSI (14)
47
Neutral
MACD trend
Positive
Bullish
52-week position
9%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+4% holders QoQ · +4 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.17% of float · ▼ -20.4% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
24 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $0
Now $1 · 9%
Range high $2
vs 200-day avg -37%
vs 50-day avg -2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ADGM
this stock
Adagio Medical Holdings, Inc.
|
$12.46M | -46.1% | — | — | 1.2% |
|
ABT
Abbott Laboratories
|
$177.58B | -18.6% | +5.7% | 28.6 | 1.3% |
|
MDT
Medtronic plc
|
$116.35B | -5.3% | +8.4% | 22.4 | 0.9% |
|
SYK
Stryker Corp
|
$105.70B | -21.6% | +11.2% | 28.6 | 2.0% |
|
BSX
Boston Scientific Corp
|
$62.29B | -54.9% | +12.5% | 17.4 | 3.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ADGM | +3.7% | -18.7% | -50.4% | +6.3% | -46.1% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | +4.9% | -17.0% | -68.2% | +6.6% | -58.1% |
Key facts
CIK
2006986
CUSIP
00534B100
13F (30d)
13 filings
13 filers
Visit website
Investor relations